Geron Corporation (GERN)
Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking pluripotent stem cells as a potential source for the manufacturing of replacement cells and tissues. Lastly, the company is researching nuclear transfer as a potential mechanism for generating genetically matched cells and tissues.
Geron Corporation (GERN)‘s Financial Overview
Geron Corporation (GERN) declined -17.86% yesterday to close its trading session at $4.23. The company has 1 year Price Target of $5.5. Geron Corporation has 52-Week high of $6.68 and 52-Week Low of $1.74. The stock touched its 52-Week High on Obsolete and 52-Week Low on Obsolete. The stock traded with the volume of 25.02 Million shares yesterday. The firm shows the market capitalization of $674 Million.
Geron Corporation (GERN) reported its last quarterly earnings on 12/30/2017 where the firm reported its Actual EPS of $-0.05/share against the analyst consensus estimate of $-0.05/share.
The firm is trading with SMA20 of 17.6 Percent, SMA50 of SMA50 Percent and SMA200 of 78.58 percent. Geron Corporation has P/S value of 612.73 while its P/B value stands at 6.51. Similarly, the company has Return on Assets of -23.4 percent, Return on Equity of -25.2 percent and Return on Investment of -28.2 Percent.
The Stock currently has Analyst’ mean Recommendation of 2.7 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 2 analysts offering 12-month price forecasts for Geron Corp have a median target of 3.75, with a high estimate of 5.00 and a low estimate of 2.50. The median estimate represents a -11.35% decrease from the last price of 4.23.
Pfizer Inc. (PFE)
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer’s Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.
Pfizer Inc. (PFE)‘s Financial Outlook
The 22 analysts offering 12-month price forecasts for Pfizer Inc have a median target of 41.50, with a high estimate of 54.00 and a low estimate of 31.00. The median estimate represents a +17.56% increase from the last price of 35.30.
According to Zacks Investment Research, Pfizer Inc. has a Consensus Recommendation of 1.77. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged0.83% and closed its last trading session at $35.3. The company has the market capitalization of $216.9 Billion. The stock has 52-week high of $39.43 and 52-Week low of $31.67. The firm touched its 52-Week high on Obsolete and 52-Week low on Obsolete. The company has volume of 24.97 Million shares. The company has a total of 6.14 Billion shares outstanding.
Pfizer Inc. (PFE) in the last quarter reported its actual EPS of $0.62/share where the analyst estimated EPS was $0.56/share. The difference between the actual and Estimated EPS is $0.06. This shows a surprise factor of 10.7 percent.
The company has YTD performance of -2.54 percent. Beta for Pfizer Inc. stands at 0.88 while its ATR (average true range) is 0.7. The company has Weekly Volatility of 2.32%% and Monthly Volatility of 1.82%.
Pfizer Inc. has distance from 20-day Simple Moving Average (SMA20) of -2.11%, Distance from 50-Day Simple Moving Average of SMA50 percent and Distance from 200-Day Simple Moving Average of 0.29%.
The Company currently has ROA (Return on Assets) of 12.5 percent, Return on Equity (ROE) of 34.3 Percent and Return on Investment (ROI) of 9.9% with Gross margin of 79.3 percent and Operating & Profit margin of 24.7% and 40.6% respectively.